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RAS GTPases mediate a wide variety of cellular functions, including cell proliferation, survival, and differentiation. Recent studies have
revealed that germline mutations and mosaicism for classical RAS mutations, including those in HRAS, KRAS, and NRAS, cause a wide
spectrum of genetic disorders. These include Noonan syndrome and related disorders (RAS/mitogen-activated protein kinase [RAS/
MAPK] pathway syndromes, or RASopathies), nevus sebaceous, and Schimmelpenning syndrome. In the present study, we identified
a total of nine missense, nonsynonymous mutations in RIT1, encoding a member of the RAS subfamily, in 17 of 180 individuals
(9%) with Noonan syndrome or a related condition but with no detectable mutations in known Noonan-related genes. Clinical
manifestations in the RIT1-mutation-positive individuals are consistent with those of Noonan syndrome, which is characterized by
distinctive facial features, short stature, and congenital heart defects. Seventy percent of mutation-positive individuals presented
with hypertrophic cardiomyopathy; this frequency is high relative to the overall 20% incidence in individuals with Noonan syndrome.
Luciferase assays in NIH 3T3 cells showed that five RIT1 alterations identified in children with Noonan syndrome enhanced ELK1 trans-
activation. The introduction of mRNAs of mutant RIT1 into 1-cell-stage zebrafish embryos was found to result in a significant increase of
embryos with craniofacial abnormalities, incomplete looping, a hypoplastic chamber in the heart, and an elongated yolk sac. These re-
sults demonstrate that gain-of-function mutations in RIT1 cause Noonan syndrome and show a similar biological effect to mutations in
other RASopathy-related genes.RAS GTPases are monomeric G proteins with a
molecular mass of 20–40 kDa and cycle between a
GTP-bound active and a GDP-bound inactive state. The
members of the RAS superfamily are structurally classified
into at least five subfamilies: RAS, Rho, Rab, Sar1/Arf,
and Ran families.1,2 The Ras subfamily consists of classical
RAS proteins (HRAS, KRAS, and NRAS), RRAS, RRAS2
(TC21), RRAS3 (MRAS), RAPs, RAEB, RALs, RIT1,
and RIT2 (RIN). RAS proteins interact with multiple
effectors, including RAF kinases, phosphatidylinositol 3-
kinase (PI-3 kinase), RalGDS, p120GAP, MEKK1, RIN1,
AF-6, phospholipase C epsilon, and the Nore-MST1
complex, and activate multiple downstream signaling
cascades.1,2 Of these signaling pathways, the RAS/
mitogen-activated protein kinase (RAS/MAPK) signaling
pathway plays a central role in cellular proliferation and
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The AmNoonan syndrome (MIM 163950) is an autosomal-domi-
nant disorder characterized by short stature, distinctive
facial features, and congenital heart defects.3,4 The distinc-
tive facial features include hypertelorism, downslanting
palpebral fissures, ptosis, a webbed or short neck, and
low-set, posteriorly rotated ears. Congenital heart defects,
including pulmonary valve stenosis and atrial septal de-
fects, occur in 50%–80% of individuals. Hypertrophic car-
diomyopathy is observed in 20% of affected individuals.
Other clinical manifestations include cryptorchidism,
mild intellectual disability, bleeding tendency, and hy-
drops fetalis. The incidence of this syndrome is estimated
to be between 1 in 1,000 to 1 in 2,500 live births. Individ-
uals with Noonan syndrome are at risk of juvenile myelo-
monocytic leukemia (JMML), a myeloproliferative disorder
characterized by excessive production of myelomonocytic
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with Costello syndrome (MIM 218040) and cardiofaciocu-
taneous (CFC) syndrome (MIM 115150).
In 2001, Tartaglia et al. identified missense mutations in
protein-tyrosine phosphatase, nonreceptor type 11
(PTPN11 [MIM 176876]), which encodes the tyrosine
phosphatase SHP-2 in 50% of individuals with Noonan
syndrome.5 In contrast, loss-of-function or dominant-
negative mutations in PTPN11 have been reported in indi-
viduals with Noonan syndrome with multiple lentigines6
(formerly referred to as LEOPARD [multiple lentigines,
electrocardiographic conduction abnormalities, ocular hy-
pertelorism, pulmonic stenosis, abnormal genitalia, retar-
dation of growth, and sensorineural deafness] syndrome
[MIM 151100]). To date, germline mutations in PTPN11,
KRAS (MIM 190070), SOS1 (MIM 182530), RAF1 (MIM
164760), and NRAS (MIM 164790) have been identified
in individuals with Noonan syndrome7–12 (NS1 [MIM
163950], NS3 [MIM 609942], NS4 [MIM 610733], NS5
[MIM 611553], and NS6 [MIM 613224]), and mutations
in SHOC2 (MIM 602775) and CBL (MIM 165360) have
been identified in two Noonan-syndrome-like syn-
dromes13–16 (NSLH [MIM 607721] and NSLL [MIM
613563], respectively) (Figure S1, available online). More-
over, we and another group have identified germlinemuta-
tions in HRAS (MIM 190020) in individuals with Costello
syndrome17 and germline mutations in KRAS, BRAF
(MIM 164757), MAP2K1 (MIM 176872), and MAP2K2
(MIM 601263) in individuals with CFC syndrome.18,19 Mu-
tations in BRAF have been also identified in a small per-
centage of individuals with Noonan syndrome (NS7
[MIM 613706]). A line of studies have shown that a group
of the above genetic disorders result from dysregulation of
the RAS and downstream signaling cascade (RAS/MAPK
pathway syndromes, or RASopathies).20,21 Recently, mosa-
icism for KRAS and HRAS mutations has been reported in
nevus sebaceous and Schimmelpenning syndrome,22
further extending a spectrum of diseases with a dysregu-
lated RAS/MAPK pathway.
To identify genetic causes of Noonan syndrome, we re-
cruited 180 individuals with Noonan syndrome or a
related phenotype; they were negative for all coding exons
in PTPN11, KRAS, HRAS, and SOS1; exons 6 and 11–16 in
BRAF; exons 7, 14, and 17 in RAF1; exons 2 and 3 in
MAP2K1 and MAP2K2; and exon 1 in SHOC2. Further ge-
netic analysis has been conducted according to their first
diagnoses.17,23–29 This study was approved by the ethics
committee of Tohoku University School of Medicine. We
obtained informed consent from all subjects involved in
the study. We sequenced the exomes of 14 individuals
whose clinical manifestations had been confirmed to be
consistent with Noonan syndrome by trained dysmor-
phologists. Targeted enrichment was performed with the
Agilent SureSelect Human All Exon v.1 Kit for four individ-
uals and with the SureSelect Human All Exon 50Mb kit for
ten individuals. Exon-enriched DNA libraries from these
14 individuals were sequenced on the Illumina Hiseq
2000 for 91 bp (v.1 kit) or 101 bp (50Mb kit). The174 The American Journal of Human Genetics 93, 173–180, July 11, 2Burrows-Wheeler Aligner (BWA) was used to align the
sequence reads to the human genome (UCSC Genome
Browser hg19);30 all BWA parameters were kept at the
default settings. After the removal of duplicates from the
alignments, realignment around known indels, recalibra-
tion, and SNP and indel calling were performed with the
Genome Analysis Toolkit (v.1.5).31 ANNOVAR was used
for annotation against the RefSeq database and dbSNP.32
We identified approximately 10,000 nonsynonymous,
nonsense, and splice-site variations and coding indels per
individual (Table S1). Filtering steps using variant data-
bases (dbSNP132 and the 1000 Genome Project database)
and in-house exome data were carried out, resulting in
the identification of 122–282 variants per individual.
By visual inspection of the generated data, four heterozy-
gous RIT1 (MIM 609591; RefSeq accession number
NM_006912.5) variants (c.246T>G [p.Phe82Leu],
c.265T>C [p.Tyr89His], c.270G>T [p.Met90Ile], and
c.284G>C [p.Gly95Ala]) were found in four individuals.
Sanger sequencing validated the heterozygous state of
the four variants. We did not find any other strong candi-
date genes in the results of exome sequencing.
RIT1 shares approximately 50% sequence identity with
RAS, has an additional N-terminal extension, and does not
possess a C-terminal CAAX motif, a specific motif for post-
translational modification.33,34 RIT1 is located in chromo-
somal region 1q22 and consists of six exons. We analyzed
an additional 166 individuals diagnosed with Noonan
syndrome or a related disorder but without mutations in
known genes.17,23–29 Sanger sequencing of all coding exons
in RIT1 in the 166 individuals showed that 13 in 166
individuals had changes. Combining with the 4 in 14 indi-
viduals from exome sequencing, a total of nine missense,
nonsynonymous mutations were identified in 17 of 180
(9%) individuals who were suspected to have Noonan syn-
drome or a related disorder (Table 1 and Figures 1A–1L).
The identified germline RIT1mutations encode alterations
located in the G1 domain (c.104G>C [p.Ser35Thr]); the
switch I region, involving the G2 domain (c.170C>G
[p.Ala57Gly]); and the switch II region, corresponding
to RAS (c.242A>G [p.Glu81Gly], c.244T>G [p.Phe82Val],
c.246T>G [p.Phe82Leu], c.247A>C [p.Thr83Pro],
c.265T>C [p.Tyr89His], c.270G>T [p.Met90Ile], and
c.284G>C [p.Gly95Ala]) (Figure S2). Amino acids where
alterations are located are conserved among species
(Figure S3). TheRIT1mutations encodealterations clustered
in the switch II region. In contrast, HRAS germline muta-
tions identified inCostello syndrome are clustered at codon
12 and 13 in the region encoding the G1 domain17
(Figure 1M). Mutations in parents were not identified in
seven families. These mutations are apparently de novo,
but biologic confirmation of parentage was not performed.
One mutation, c.104G>C, was inherited from a mother
with a Noonan syndrome phenotype (Table 1). None of
these mutations were identified in 480 controls.
To assess the functional consequences of RIT1 mu-
tations identified in affected individuals, we introduced a013
Table 1. Mutations in RIT1, Family Status, and Heart Defects of Mutation-Positive Individuals
Subject Exon Nucleotide Changea Amino Acid Changeb Father Mother HCMc PSc Other Heart Defectsc
NS414 2 c.104G>C p.Ser35Thr WT p.Ser35Thr þ – MVP, MR
KCC27 2 c.104G>C p.Ser35Thr NA NA þ þ –
NS43 4 c.170C>G p.Ala57Gly NA NA þ – MR, TR
NS185 4 c.170C>G p.Ala57Gly NA NA þ þ ASD, PDA
NS216 4 c.170C>G p.Ala57Gly NA NA þ – –
NS402 4 c.170C>G p.Ala57Gly WT WT þ þ –
NS168 5 c.242A>G p.Glu81Gly NA NA – þ VSD
NS410 5 c.244T>G p.Phe82Val WT WT þ – –
NS358 5 c.246T>G p.Phe82Leu WT WT – þ ASD
NS465 5 c.246T>G p.Phe82Leu NA NA – þ VSD
NS276 5 c.247A>C p.Thr83Pro WT WT þ þ PVC
KCC8 5 c.265T>C p.Tyr89His NA NA þ þ –
KCC38 5 c.270G>T p.Met90Ile WT WT þ þ ASD, VSD, PDA
NS234 5 c.284G>C p.Gly95Ala WT WT – – ASD
NS265 5 c.284G>C p.Gly95Ala WT WT þ þ –
Og22 5 c.284G>C p.Gly95Ala NA NA – – –
Og45 5 c.284G>C p.Gly95Ala NA NA þ þ ASD
PCR primers used for sequencing are shown in Table S3. Nucleotide changes are not located in CpG dinucleotides, suggesting that they exhibit baseline mutation
rates with a phenotypic filtering effect and that only these mutations lead to this phenotype. Abbreviations are as follows: WT, wild-type; HCM, hypertrophic
cardiomyopathy; PS, pulmonic stenosis; MVP, mitral valve prolapse; MR, mitral regurgitation; TR, tricuspid regurgitation; ASD, atrial septal defect; PDA, patent
ductus arteriosus; VSD, ventricular septal defect; PVC, premature ventricular contraction; and NA, not available.
aRefSeq NM_006912.5.
bRefSeq NP_008843.1.
cHCM and heart anomalies were diagnosed by echocardiography.single-base substitution (p.Ser35Thr, p.Ala57Gly,
p.Glu81Gly, p.Phe82Leu, or p.Gly95Ala) identified in indi-
viduals with Noonan syndrome into a pCAGGS expression
vector36 harboring RIT1 cDNA. As an experimental con-
trol, cDNAs harboring RIT1 c.89G>T (p.Gly30Val),
c.104G>C (p.Ser35Asn), and c.236A>T (p.Gln79Leu) and
Braf c.1910T>A (p.Val637Glu) (RefSeq NM_139294),
which corresponds to oncogenic p.Val600Glu in humans,
were also generated. RIT1 p.Gly30Val and p.Gln79Leu
correspond to oncogenic RAS alterations p.Gly12Val and
p.Gln61Leu, respectively. We introduced pFR-luc, pFA2-
Elk1, phRLnull-luc, and wild-type (WT) or mutant expres-
sion constructs of RIT1 into NIH 3T3 cells to examine the
transcriptional activation by ELK1,18,33 a transcription fac-
tor that is activated by MAPK. The results revealed that
compared with the WT cDNA, all RIT1 mutations ex-
hibited significant activation. RIT1 p.Gln79Leu, followed
by p.Gly95Ala, p.Ala57Gly, p.Phe82Leu, and p.Glu81Gly,
showed the highest ELK1 transactivation, as also shown
in a past study37 (Figure 2A). The c.104G>C (p.Ser35Thr)
substitution was identified in two affected individuals.
RIT1 p.Ser35Asn, which corresponds to dominant-nega-
tive alteration p.Ser17Asn in RAS, has been used as a domi-
nant-negative substitution in cell experiments.38 To
examine the functional consequence of p.Ser35Thr, identi-The Amfied in affected individuals, we compared the ELK1 transac-
tivation in cells expressing p.Ser35Thr and those express-
ing p.Ser35Asn. Enhanced ELK1 transactivation was
observed in cells expressing p.Ser35Thr, but not in cells
expressing p.Ser35Asn (Figure 2B). These results suggest
that RIT1 mutations identified in affected individuals
were gain-of-function mutations.
RIT1 is expressed ubiquitously in embryonic and adult
tissues.33,34 Rit1-null mice have been shown to grow to
adulthood without any apparent abnormalities;39 hence,
physiological roles of RIT1 in development remain un-
known. To examine the developmental effect of identified
mutations, we introducedmRNA of theWTand three RIT1
mutations (c.236A>T [p.Gln79Leu], c.242A>G
[p.Glu81Gly], and c.284G>C [p.Gly95Ala]) into 1-cell-
stage zebrafish embryos and observed the phenotype at
11 hr postfertilization (hpf). An oval-shaped egg sack, a
typical manifestation of the gastrulation defect, was
observed in embryos expressing RIT1 alterations (Fig-
ure 3A). This characteristic shape change was also observed
in zebrafish expressing gain-of-function mutations of
human NRAS40. Next, we observed the phenotype at later
stages (48–52 hpf) (Figure 3B and Figure S4). The introduc-
tion of the WT mRNA did not interfere with the normal
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Figure 1. Photographs of Six Individuals
in whom RIT1 Mutations Were Identified
(A–D) KCC38 at 3 years of age. Broad fore-
head, sparse eyebrows, ptosis, hypertelor-
ism, and hyperpigmentation were
observed (A and B). Prominent finger
pads were observed (C and D).
(E–H) NS358 at 4 years of age. Hypertelor-
ism, epicanthus, sparse eyebrows, and
low-set ears were observed.
(I) NS414 at 3 years of age.
(J) NS465 at 1 year of age.
(K) NS276 at 5 months.
(L) NS265 at 5 years of age.
(M) Structure and identified germline alter-
ations in RIT1 and HRAS. HRAS alterations
identified in individuals with Costello syn-
dromewere described before20 or shown in
The RAS/MAPK Syndromes Homepage (see
Web Resources). HRAS alterations identi-
fied in individuals with congenital myop-
athy with excess of muscle spindles35 are
indicated in purple.
We obtained specific consent for photo-
graphs from six individuals.in 125/132 (94.7%) embryos; however, 7/132 (5.3%) em-
bryos had limited mild craniofacial and heart abnormal-
ities (Table 2). In contrast, a combined manifestation of
craniofacial abnormalities, pericardial edema, and an elon-
gated yolk sac was observed in 66.1%, 52.4%, and 40.5%
of embryos expressing p.Gln79Leu, p.Glu81Gly, and
p.Gly95Ala, respectively. Development was severely
retarded in approximately 7% of embryos expressing
RIT1 alterations; these embryos displayed the formation
of a disorganized round body shape with a dysmorphic
head and body trunk. In the head region, a hypoplastic176 The American Journal of Human Genetics 93, 173–180, July 11, 2013brain, especially in the telencephalic
area, was observed and resulted in
misshapen morphology. In the
ventral part of the head, the jaw
structure was also hypoplastic, and
the eyes were translocated medially.
These morphological changes gave a
cyclopia-like appearance. The ventral
sides of the eyes were small, and colo-
boma along with a loss of pigment
was evident (Figure 3B). These pheno-
typic changes are compatible with
the gastrulation defect observed at
11 hpf (Figure 3A). Because the Fgf/
Ras/MAPK signaling cascade plays an
essential role in the convergent
and extension cell movement during
gastrulation,41 perturbation by
the RIT1 alterations could cause
abnormal cell movement in the axial
portions and thus lead to an elon-
gated shape of the egg and the hypo-
plastic ventral side of the head.Detailed inspection of the morphology in mutant-injected
embryos revealed abnormal cardiogenesis, namely, incom-
plete looping, hypoplastic chambers, and stagnation of
blood flow in the yolk sac (Figure 3B). Although the atrium
of these hearts beat regularly, the ventricle seemed to
twitch passively by the contraction of the atrium (Movies
S1, S2, S3, S4, S5, and S6). These results indicate that acti-
vating mutations in RIT1 induce abnormal craniofacial
and heart defects in zebrafish.
RIT1-mutation-positive individuals showed a distinct
facial appearance, congenital heart defects, and skeletal
Figure 2. Stimulation of ELK Transcrip-
tion in NIH 3T3 Cells Expressing RIT1
Germline Mutations
(A) The ELK1-GAL4 vector and the GAL4
luciferase trans-reporter vector were tran-
siently transfected with various RIT1 germ-
line mutations and activatingmutations in
BRAF and MAP2K1 in NIH 3T3 cells.
c.1910T>A (p.Val637Glu) in mouse Braf
corresponds to oncogenic c.1799T>A
(p.Val600Glu) in human BRAF. Relative
luciferaseactivitywas calculatedbynormal-
ization to the activity of a cotransfected
control vector, phRLnull-luc, containing
distinguishable R. reniformis luciferase.
(B) ELK1 transactivation in cells express-
ing p.Ser35Thr, identified in individuals
with Noonan syndrome, and p.Ser35Asn,
were examined. p.Ser35Asn corresponds to
dominant-negative alteration p.Ser17Asn
in RAS.
Results are expressed as the means of quadruplicate (A) and triplicate (B) samples. Error bars represent the SDs of mean values. Red bars
indicate germline RIT1mutations identified in Noonan syndrome. The following abbreviation is used:WT, wild-type. *p< 0.01 by t test.abnormalities and were diagnosed with Noonan syn-
drome by diagnostic criteria developed by van der Burgt
(Figures 1A–1L and Table 1).4 Two individuals (NS358
and KCC38) were suspected to have CFC syndrome in
the infantile period because of curly, sparse hair, a high
cranial vault, and hypoplasia of the supraorbital ridges.
Nine individuals showed perinatal abnormality,
including polyhydramnios, nuchal translucency, and
chylothorax (Table S2). It is of note that one individual
(Og45) showing severe pleural effusion, hypertrophic
cardiomyopathy, and hepatomegaly that ended in severe
body edema and compromised circulation died 53 days
after birth. Seven individuals showed high birth weight,
probably as a result of subcutaneous edema, which is a
typical manifestation observed in individuals with
Noonan syndrome.4 Out of 17 affected individuals, 16
(94%) had heart defects (Table 1): hypertrophic cardio-
myopathy (HCM) in 12 (71%) individuals, pulmonary
stenosis in 11 (65%) individuals, and atrial septal
defects in 5 (29%) individuals. The incidence of
pulmonic stenosis and mild cognitive defects is close
to the overall incidence of these features in Noonan
syndrome cohorts. By contrast, the incidence of HCM
is far greater than in individuals with Noonan syn-
drome overall (25/118 in Noonan syndrome42 versus
12/17 in individuals with RIT1 mutations; p < 0.0001
by Fisher’s exact test). It is of note that a high fre-
quency of HCM (70%) was also reported in individuals
with RAF1 mutations.10,11,24 It is possible that RIT1
interacts with RAF1 and that gain-of-function muta-
tions in RIT1 and RAF1 exert similar effects in heart
development.
Somatic alterations in classical RAS have been identified
in approximately 30% of tumors.43 Noonan syndrome and
related disorders confer an increased risk of developing
malignant tumors.20,44 In a summary of the literature, it
has been reported that 45 of 1,151 (3.9%) individualsThe Amwith Noonan syndrome (but with an unknown mutation
status) developed malignant tumors.44 Since molecular
analysis became available, gene-specific association with
malignant tumors has been revealed. The association
with JMML, a myeloproliferative disorder characterized
by the excessive production of myelomonocytic cells,
has been reported in individuals with PTPN11, CBL, and
KRAS mutations. Recent reports showed that two individ-
uals with SOS1 mutations developed embryonal rhabdo-
myosarcoma.45,46 A somatic RIT1 variant, c.270G>A
(p.Met90Ile), has been identified in lung cancer (COSMIC
database). In the present cohort, 1 (NS168) of 17 individ-
uals with RIT1 c.242A>G (p.Glu81Gly) developed acute
lymphoblastic leukemia at the age of 5 years. The child
was treated by a standard protocol and has remained in
complete remission. Examining whether gain-of-function
mutations in RIT1 cause tumorigenesis will require further
study.
RIT1 has been isolated as a cDNA encoding highly
conserved G3 and G4 domains of RAS proteins33 or
identified as a gene encoding a protein related to
Drosophila Ric, a calmodulin-binding RAS-related
GTPase.34 RIT1 p.Gln79Leu, which corresponds to RAS
p.Gln61Leu, is implicated in transforming NIH 3T3 cells,
neurite outgrowth in neuronal cells, and the activation
of ERK and p38 MAPK in a cell-specific manner.37,38,47
In this study, enhanced ELK1 transactivation was
observed in cells expressing mutant RIT1 cDNAs. Previous
studies showed that enhanced ELK transactivation
was observed in NIH 3T3 cells expressing HRAS, KRAS,
BRAF, and RAF1 mutations identified in individuals
with Costello, CFC, and Noonan syndromes.17,18,24
Gastrulation defects observed in zebrafish embryos
expressing RIT1 alterations (p.Glu81Gly, p.Gly95Ala,
or p.Gln79Leu) were also reported in zebrafish em-
bryos expressing an activating mutation in NRAS,
BRAF, MAP2K1, or MAP2K2.40,48 Taken together, theseerican Journal of Human Genetics 93, 173–180, July 11, 2013 177
Figure 3. Morphology of Embryos In-
jected with the WT or Mutant RIT1 mRNA
In vitro transcription of each mRNA
was performed with the mMESSAGE
mMACHINE kit (Applied Biosystems)
according to the manufacturer’s instruc-
tions. Synthesized mRNAs were purified
with G-50 Micro Columns (GE Healthcare)
and subsequently adjusted to a 300 ng/ml
concentration for microinjection. Approxi-
mately 1 nl (300 pg) of RNA in water with
0.2% phenol red was injected into the cyto-
plasm of 1-cell-stage zebrafish embryos.
Injected embryos were incubated at 28C
until observation.
(A) At 11 hpf, the shapes of the em-
bryos injected with the WT sense or anti-
sense mRNA were round, a normal
morphology as observed in the uninjected
embryos. In contrast, embryos express-
ing mutations (c.236A>T [p.Gln79Leu],
c.242A>G [p.Glu81Gly], and c.284G>C
[p.Gly95Ala]) are oval and compressed
along the dorsal-ventral axis, indicative
of a gastrulation defect. Note that cells
have a hump in the head region at the anterior end of the body axis, the earliest manifestation of a craniofacial defect.
(B) Lateral views at 48 hpf are shown. Embryos expressing mutations (c.236A>T [p.Gln79Leu], c.242A>G [p.Glu81Gly], and c.284G>C
[p.Gly95Ala]) formed swollen yolk sacs equally along the anterior posterior axis but did not show narrowing in the caudal half, which
was clearly visible in the uninjected embryos and in those injected with the WT sense or antisense mRNA. In the craniofacial area,
misshapen head and jaw structures and small eyes with hypoplasia on the ventral side were observed (middle panel); these phenotypes
are consistent with the gastrulation defect. Shapes of the hearts (highlighted by red dotted lines) are shown in the right panel at a higher
magnification. Normal looping of the heart tube and correct formation of two distinct chambers are observed in embryos injected with
the WT sense or antisense mRNA. When mutations (c.236A>T [p.Gln79Leu], c.242A>G [p.Glu81Gly], and c.284G>C [p.Gly95Ala])
were expressed, looping was incomplete, resulting in stretched straight heart tubes. Constrictions at the atrial-ventricular canal are
obscure, and the heart chambers are hypoplastic. Abbreviations are as follows: A, atrium; and V, ventricle.results indicate that gain-of-function mutations in RIT1
cause Noonan syndrome and show a similar effect to mu-
tations in other RASopathy-related genes in human devel-
opment.
Herein, we used whole-exome sequencing to identify
germline RIT1mutations in individuals with Noonan syn-
drome, a disorder of the RASopathies. Mutations in
PTPN11, SOS1, RAF1, KRAS, BRAF, and NRAS have been
identified in 41%, 11%, 5%, 1%, 0.8%, and 0.2% of all
cases, respectively,3 and thus the frequency of RIT1 muta-
tions in Noonan syndrome might be similar to that of
RAF1 mutations. Our findings will improve diagnostic
accuracy of Noonan syndrome and provide a clue to un-
derstanding the disorder’s pathogenesis, including thera-
peutic approaches.Table 2. Morphologic Abnormality at 48–52 hpf of Zebrafish Embryo
No Abnormalities Heart and Facial Abnormalit
WT 125 7 (5.3%)
p.Gln79Leu 31 78 (66.1%)
p.Glu81Gly 42 55 (52.4%)
p.Gly95Ala 44 34 (40.5%)
aCraniofacial abnormalities, pericardial heart edema, and an elongated yolk sac w
bDisorganized round body shape with a dysmorphic head and body trunk as sho
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Supplemental Data include four figures, three tables, and six
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